Galsulfase

Drug Profile

Galsulfase

Alternative Names: arylsulfatase B; Aryplase™; BM 102; Naglazyme; Recombinant human arylsulfatase B; recombinant human N-acetylgalactosamine-4-sulfatase; rhASB

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BioMarin Pharmaceutical
  • Developer AnGes MG; BioMarin Pharmaceutical; Medison Pharma
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action N acetylgalactosamine 4 sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis VI

Most Recent Events

  • 25 Nov 2011 Launched for Mucopolysaccharidosis VI in Russia (IV)
  • 06 Apr 2011 Launched for Mucopolysaccharidosis VI in Switzerland (IV)
  • 31 Dec 2010 Launched for Mucopolysaccharidosis VI in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top